Tenofovir disoproxil fumarate


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Chronic hepatitis B
Adult: 300 mg once daily.
Child: ≥2 years weighing >10 kg: 8 mg/kg once daily. Max: 300 mg daily.

Oral
HIV infection
Adult: In combination with other antiretrovirals: 300 mg once daily.
Child: ≥2 years weighing >10 kg: 8 mg/kg once daily. Dosage recommendations may vary among individual products and between countries (refer to detailed product guideline).
Suy thận
Haemodialysis patients: 300 mg once every 7 days or after a cumulative total of 12 hours of dialysis.
CrCl (mL/min) Dosage
10-29 300 mg 72-96 hourly.
30-49 300 mg 48 hourly.
Chống chỉ định
Hypersensitivity. Lactation.
Thận trọng
Patient with risk factors for liver disease; coinfection with HIV and HBV. Renal and hepatic impairment. Pregnancy.
Tác dụng không mong muốn
Significant: Decreased bone mineral density, immune reconstitution syndrome, osteomalacia with proximal renal tubulopathy, acute renal failure and/or Fanconi syndrome.
Gastrointestinal disorders: Diarrhoea, vomiting, nausea, abdominal pain, abdominal distention, flatulence.
General disorders and administration site conditions: Asthenia, fatigue, fever.
Metabolism and nutrition disorders: Hypophosphataemia.
Nervous system disorders: Dizziness, headache.
Psychiatric disorders: Insomnia, depression.
Skin and subcutaneous tissue disorders: Rash, urticaria, pruritus.
Potentially Fatal: Lactic acidosis, severe hepatomegaly with steatosis.
PO: Z (Current evidence suggests that tenofovir disoproxil does not increase the risk of pregnancy-related adverse effects. Tenofovir disoproxil is one of the recommended antiviral agents in management of HIV and/or hepatitis B during pregnancy.)
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor renal function and serum phosphate concentrations before the start of therapy, within the first 4 weeks of treatment, after 3 months of treatment, and every 3-6 months thereafter; bone density at baseline and during treatment; LFT every 3 months during therapy and for several months following discontinuation. Determine HIV status in all hepatitis B virus (HBV) infected patients prior to treatment.
Tương tác
May decrease the plasma concentrations of atazanavir and increased plasma concentration of tenofovir disoproxil fumarate when given concomitantly. May increase the plasma concentrations of didanosine. Increased risk of nephrotoxicity with drugs that reduce renal function (e.g. cidofovir, aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin). Decreased therapeutic effect with adefovir.
Tương tác với thức ăn
High fat meals may increase bioavailability of tenofovir.
Tác dụng
Description: Tenofovir disoproxil fumarate (TDF) is a prodrug of tenofovir. It interferes with DNA synthesis of HIV through competitive inhibition of reverse transcriptase and incorporation into viral DNA. It also inhibits hepatitis B virus polymerase, resulting in inhibition of viral replication.
Pharmacokinetics:
Absorption: Rapidly absorbed from the gastrointestinal tract. Increased bioavailability when taken with a high fat meal. Bioavailability: Approx 25%. Time to peak plasma concentration: 36-84 minutes (fasting); 96-144 minutes (with high fat meal).
Distribution: Widely distributed into body tissues, particularly the kidneys and liver. Volume of distribution: 1.2-1.3 L/kg. Plasma protein binding: <7%.
Metabolism: Tenofovir disoproxil fumarate is rapidly converted intracellularly to tenofovir via hydrolysis, and subsequently phosphorylated to the active form, tenofovir diphosphate.
Excretion: Via urine (70-80%, as unchanged drug). Elimination half-life: 17 hours.
Đặc tính

Chemical Structure Image
Tenofovir disoproxil fumarate

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 6398764, Viread. https://pubchem.ncbi.nlm.nih.gov/compound/Viread. Accessed Feb. 23, 2021.

Bảo quản
Store at 25°C.
Phân loại MIMS
Thuốc kháng virus
Phân loại ATC
J05AF07 - tenofovir disoproxil ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Tài liệu tham khảo
Anon. Tenofovir Disoproxil Fumarate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/02/2021.

Buckingham R (ed). Tenofovir Disoproxil Fumarate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/02/2021.

Tenofovir Disoproxil Accordpharma 245 mg Film-coated Tablets (Accord Healthcare Limited). MHRA. https://products.mhra.gov.uk. Accessed 05/02/2021.

Viread Tablet, Coated, Powder (Gilead Sciences, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/02/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Tenofovir disoproxil fumarate từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Agifovir
  • Edar
  • Getino-B
  • Glonovir
  • Mibeproxil
  • Minovir
  • Planovir
  • SaVi Tenofovir
  • Tenifo
  • Tenofovir F.T. Pharma
  • Tevir
  • Topflovir
  • Viread
  • Virkil
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in